Sonnet BioTherapeutics Holdings, Inc. (SONN) Earnings History
Net Loss18 years of earnings data (2008–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Sonnet BioTherapeutics Holdings, Inc. (SONN) Earnings Overview
As of June 29, 2026, Sonnet BioTherapeutics Holdings, Inc. (SONN) reported trailing twelve-month net income of -$14M, reflecting +65.2% year-over-year growth. The company earned $-3.42 per diluted share over the past four quarters, with a net profit margin of -1611.3%.
Looking at the long-term picture, SONN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$813,696 in fiscal 2009.
Sonnet BioTherapeutics Holdings, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ALDX (-$27M net income), CRVS (-$44M net income), IMMP (-$128M net income, -1218.0% margin), SONN has comparable earnings metrics. Compare SONN vs ALDX →
SONN Earnings vs Peers
Earnings metrics vs comparable public companies
SONN Historical Earnings Data (2008–2025)
17 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$16M | -116.6% | -$16M | $-3.95 | -1611.3% | -1584.4% |
| 2024 | -$7M | +60.5% | -$12M | $-11.35 | -39929.3% | -63617.9% |
| 2023 | -$19M | +36.7% | -$19M | $-145.12 | -12741.6% | -12714.5% |
| 2022 | -$30M | -19.1% | -$30M | $-1203.05 | -8508.3% | -8478.3% |
| 2021 | -$25M | -3.1% | -$25M | $-2507.83 | -5170.5% | -5187.4% |
| 2020 | -$24M | -398.1% | -$17M | $-17159.00 | - | - |
| 2019 | -$5M | +28.9% | -$5M | $-163753.00 | -12.0% | -11.6% |
| 2018 | -$7M | -0.9% | -$3M | $-126904.00 | -22.3% | -10.0% |
| 2017 | -$7M | +25.1% | -$3M | $-175138.00 | -16.4% | -6.1% |
| 2016 | -$9M | +25.2% | -$3M | $-269068.00 | -21.8% | -6.3% |
| 2015 | -$12M | -103.6% | -$11M | $-544544.00 | -28.6% | -27.1% |
| 2013 | -$6M | -88.3% | -$6M | $-768768.00 | -34.1% | -33.1% |
| 2012 | -$3M | -187.0% | -$3M | $-800800.00 | -46.0% | -41.7% |
| 2011 | -$1M | -9.1% | $-714,305 | $-382205.00 | -75.4% | -48.8% |
| 2010 | -$1M | -24.3% | $-809,888 | $-505782.50 | -742.2% | -594.2% |
| 2009 | $-813,696 | +63.7% | $-444,487 | $-538137.00 | -118.8% | -64.9% |
| 2008 | -$2M | - | $-949,991 | $-999999.00 | -956.4% | -405.9% |
Download Data
Export SONN earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
18+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SONN — Frequently Asked Questions
Quick answers to the most common questions about buying SONN stock.
What is SONN earnings per share (EPS)?
SONN trailing twelve-month (TTM) diluted EPS is $-3.42, reflecting +65.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2008 to 2025 is available in the table on this page.
What is Sonnet BioTherapeutics Holdings, Inc.'s net income?
Sonnet BioTherapeutics Holdings, Inc. (SONN) trailing twelve-month net income is $-14M as of 2025. Earnings grew +65.2% year-over-year.
Is SONN profitable?
SONN is not currently profitable on a TTM basis, reporting a net loss of $-14M. Net margin is -1611.3%. Investors should monitor for a return to profitability.
What is SONN's earnings growth rate?
SONN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2008 to 2025.
What are SONN's profit margins?
Sonnet BioTherapeutics Holdings, Inc. net profit margin is -1611.3%, operating margin is -1584.4%, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -312.8%.
Is SONN growing earnings?
Yes, SONN earnings are accelerating — EPS growth of +65.2% exceeds the 5-year CAGR of N/A. TTM net income reached $-14M. Earnings momentum is strengthening.
What was SONN's best earnings year?
Sonnet BioTherapeutics Holdings, Inc.'s highest annual net income on record is $-813696.00, achieved in fiscal year 2009. Earnings history on this page spans 2008 to 2025 and includes all annual and quarterly figures.
What were SONN's earnings last quarter?
SONN's most recent reported quarter was Q3 2025. Net income was $-4M with diluted EPS of $-0.95. For a full breakdown of all quarters, see the quarterly earnings table on this page.